Utilization of PROMs in hypo-fractionated radiotherapy for localized prostate cancer

Karen Crowther, A Cole, P Shiels, S Jain, Paul Shepherd, D Mitchell

Research output: Contribution to conferenceAbstractpeer-review


Patient Reported Outcome Measures (PROMS) are a useful metric in evidence-based clinical care and translational research. Recording toxicities of treatments and impact on patients’ Quality of Life (QoL) can be useful in counselling future patients to aid decision-making. Real time PROMS have the ability to improve patient care and guide changes to therapy. Curative treatment options for prostate cancer (PCa) include prostatectomy, brachytherapy, external beam radiotherapy (EBRT) and combination therapy utilising EBRT followed by High Dose Rate Brachytherapy (HDR-BT). There is a paucity of evidence comparing PROMS for newer radiotherapy techniques .This prospective study tested feasibility of collecting multiple PROMS in PCa patients comparing PROMS for HDR-BT combined with hypo-fractionated EBRT (hEBRT) (Combination Group) and hEBRT alone (Monotherapy Group).
This small study showed excellent patient compliance with completion of PROMS. Both treatment groups tolerated treatment well and there was minimal impact on QoL. In relation to treatment-related symptoms, the monotherapy group reported a higher incidence of bowel toxicity although this improved after the completion of treatment. The feasibility of collecting multiple PROMS is evidenced in this study, streamlining of these tools into integrated technology applications and real time PROMS measurement has the ability to benefit patients and guide clinicians in adapting therapies based on individual need.
Original languageEnglish
Publication statusPublished (in print/issue) - 9 Nov 2019
EventAll Ireland radiation Therapy Study Day - Galway, Ireland, Galway
Duration: 9 Nov 20199 Nov 2019


ConferenceAll Ireland radiation Therapy Study Day


Dive into the research topics of 'Utilization of PROMs in hypo-fractionated radiotherapy for localized prostate cancer'. Together they form a unique fingerprint.

Cite this